MiR-125b, miR-100 and miR-99a co-regulate vincristine resistance in childhood acute lymphoblastic leukemia.
暂无分享,去创建一个
R. Pieters | M. D. Den Boer | R. Pieters | M. L. Boer | I. Ariës | F. Moqadam | F. Akbari Moqadam | E. Lange-Turenhout | M. D. den Boer
[1] Wei Xu,et al. Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia , 2012, Medical Oncology.
[2] A. Borkhardt,et al. MiR-125 in normal and malignant hematopoiesis , 2012, Leukemia.
[3] M. R. Hough,et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. , 2012, Blood.
[4] Si-yong Huang,et al. miR-153 sensitized the K562 cells to As2O3-induced apoptosis , 2012, Medical Oncology.
[5] Bo W. Han,et al. Down-regulated miR-331–5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia , 2011, Journal of cellular and molecular medicine.
[6] Ling Xu,et al. A set of miRNAs that involve in the pathways of drug resistance and leukemic stem-cell differentiation is associated with the risk of relapse and glucocorticoid response in childhood ALL , 2011, Human molecular genetics.
[7] J. Lieberman,et al. Conserved Regulation of p53 Network Dosage by MicroRNA–125b Occurs through Evolving miRNA–Target Gene Pairs , 2011, PLoS genetics.
[8] Hua Zhang,et al. Upregulation of microRNA-125b contributes to leukemogenesis and increases drug resistance in pediatric acute promyelocytic leukemia , 2011, Molecular Cancer.
[9] M. D. Boer,et al. Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia , 2011, Leukemia.
[10] Y. You,et al. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. , 2011, International journal of oncology.
[11] Gang Chen,et al. miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1 , 2011, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.
[12] Y Enomoto,et al. Eμ/miR-125b transgenic mice develop lethal B-cell malignancies , 2011, Leukemia.
[13] R. Agami,et al. MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression , 2011, Cell cycle.
[14] Caifu Chen,et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia , 2011, Haematologica.
[15] Debashis Sahoo,et al. MicroRNA-125b expands hematopoietic stem cells and enriches for the lymphoid-balanced and lymphoid-biased subsets , 2010, Proceedings of the National Academy of Sciences.
[16] V. Thayanithy,et al. Regulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217* , 2010, The Journal of Biological Chemistry.
[17] Beiyan Zhou,et al. MicroRNA miR-125b causes leukemia , 2010, Proceedings of the National Academy of Sciences.
[18] J. Fei,et al. Anti-miR-21 oligonucleotide enhances chemosensitivity of leukemic HL60 cells to arabinosylcytosine by inducing apoptosis , 2010, Hematology.
[19] Aadel A. Chaudhuri,et al. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output , 2010, Proceedings of the National Academy of Sciences.
[20] Wei Xiong,et al. MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression* , 2010, The Journal of Biological Chemistry.
[21] Xianghuo He,et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3′ untranslated region , 2010, Oncogene.
[22] S. Armstrong,et al. A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 Acute Lymphocytic Leukemia cells , 2010, Cell cycle.
[23] S. Orkin,et al. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. , 2010, Genes & development.
[24] Epaminondas Doxakis,et al. Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153 , 2010, The Journal of Biological Chemistry.
[25] Francesca Meloni,et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. , 2010, Blood.
[26] M. Davis,et al. An endogenous positively selecting peptide enhances mature T cell responses and becomes an autoantigen in the absence of microRNA miR-181a , 2009, Nature Immunology.
[27] Oliver Hofmann,et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. , 2009, Molecular cell.
[28] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[29] Dominique Leroux,et al. Myeloid cell differentiation arrest by miR-125b-1 in myelodysplasic syndrome and acute myeloid leukemia with the t(2;11)(p21;q23) translocation , 2008, The Journal of experimental medicine.
[30] Christina Thaller,et al. miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis , 2008, Nature Neuroscience.
[31] Jae Hoon Kim,et al. MicroRNA Expression Profiles in Serous Ovarian Carcinoma , 2008, Clinical Cancer Research.
[32] Rudolf Jaenisch,et al. Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17∼92 Family of miRNA Clusters , 2008, Cell.
[33] N. Field,et al. vFLIP from KSHV inhibits anoikis of primary endothelial cells , 2008, Journal of Cell Science.
[34] J. Steitz,et al. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.
[35] C. Croce,et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[36] Cheng Cheng,et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.
[37] R. Pieters,et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. , 2000, Blood.
[38] G. Ruvkun,et al. Negative regulatory sequences in the lin-14 3'-untranslated region are necessary to generate a temporal switch during Caenorhabditis elegans development. , 1991, Genes & development.
[39] Hong-zhao Li,et al. Differential miRNA expression profiles in bladder urothelial carcinomas. , 2010, Asian Pacific journal of cancer prevention : APJCP.
[40] W. Xiong,et al. MICRORNA-125 B CONFERS THE RESISTANCE OF BREAST CANCER CELLS TO PACLITAXEL THROUGH SUPRESSION OF PRO-APOPTOTIC BCL-2 ANTAGONIST KILLER 1 ( BAK 1 ) EXPRESSION , 2010 .
[41] Marina Bousqueta,et al. MicroRNA miR-125 b causes leukemia , 2010 .
[42] Noam Shomron,et al. Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53 , 2009, Leukemia.